A case-control study of the association between metabolic syndrome and colorectal cancer: a comparison of International Diabetes Federation, National Cholesterol Education Program Adults Treatment Panel III, and World Health Organization definitions

Ulaganathan, Vaidehi; Kandiah, Mirnalini; Shariff, Zalilah Mohd

doi:10.21037/jgo.2018.04.01

Cited by 15 publications

(13 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of case-control studies are similar and in agreement with our findings (9,29) and also a systematic review study (15). Moreover, in the present study and the study by Ulaganathan et al (18), obesity and low HDL were the components of MetS that increased CRC risk.…”

Section: Discussionsupporting

confidence: 93%

“…Prospec-tive (10) and systematic review studies (8,15) in the world have been conducted to identify the relation of the history of DM and MetS to CRC, but the present research is one of the rare studies was conducted in Iran. Our results are completely consistent with the findings of studies in other countries, including the case-control studies of Woo et al in Korea (17), Ulaganathan (18), and Cavicchia et al in the USA (19).…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Metabolic Syndrome and Risk of Colorectal Cancer: A Case-Control Study

et al. 2019

View full text Add to dashboard Cite

Background: Among Middle East countries, the prevalence of Metabolic Syndrome (MetS) and Type 2 Diabetes Mellitus (T2DM) dramatically increased in Iran. Very few evidence-based studies have been performed on the relationship between metabolic disorders and colorectal cancer (CRC) in developing countries at least in Iran. Objectives: This case-control study aimed to determine the relationship between MetS and CRC risk. Methods: A case-control study with 414 participants (207 cases and 207 controls) was conducted among referral hospitals (Imam Reza, Shahid Madani, and Sina) in Tabriz, Azerbaijan province, Iran. Cases with CRC confirmed by positive pathology and colonoscopy findings were selected and compared with the controls without neoplastic and chronic diseases at the same time and hospitals for the cases. Group matching was used based on sex and age variables for the case and control groups. MetS was defined by the International Diabetes Federation (IDF) criteria. Multiple logistic regression was used to estimate adjusted odds ratios for the association between MetS and odds of CRC. Results: Out of 414 participants, 220 (53%) were men. Among the cases, 134 (64.73%) patients had MetS, while in the control group, 82 individuals (39.61) had MetS history. After adjusting for the confounders, MetS and DM history were significantly associated with elevated odds of CRC (OR: 2.79, %95 CI: 1.58-5.15, P = 0.001) and (OR: 2.57, %95 CI: 1.25-4.58, P = 0.006), respectively. We have observed also a dose-response relation and a trend between the components of MetS and CRC risk. So, the odds of CRC increased by rising numbers of MetS components. Conclusions: It seems that MetS and its components are associated with an increased risk of CRC.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionsupporting

confidence: 93%

Metabolic Syndrome and Risk of Colorectal Cancer: A Case-Control Study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, in this current meta-analysis, there is no significance between the two different cancer sites. A study conducted in South Asians, indicated that definition of MetS by the IDF is the most sensitive in predicting the risk of CRC, compared to MetS as defined by the WHO and ATP III [56]. According to our meta-analysis, MetS increased the risk of CRC as defined either IDF or ATPIII, other than defined as AHA.…”

Section: Discussionmentioning

confidence: 59%

The association of Metabolic Syndrome and its Components with the Incidence and Survival of Colorectal Cancer: A Systematic Review and Meta-analysis

Han¹,

Wu²,

Zhang³

et al. 2021

Int. J. Biol. Sci.

View full text Add to dashboard Cite

Background: This meta-analysis was aimed to quantitatively assess the associations of metabolic syndrome (MetS) and its components with colorectal cancer (CRC). Methods: PubMed, EMBASE and Web of Science databases were systematically searched for eligible studies. A total of 18 studies for CRC incidence and 12 studies for CRC mortality were identified. Results: MetS was associated with an increased risk of CRC incidence and mortality in male (RR: 1.28, 95 % CI 1.16-1.39, and 1.24, 1.18-1.31, respectively) and correlated with an increased risk of CRC incidence in female (RR: 1.21, 1.13-1.30), but not with CRC mortality in female. MetS increased the risk of cancer-specific mortality (RR: 1.72, 1.03-2.42), but not overall mortality. The risk estimates of CRC incidence changed little depending on age, sex, cancer site, the type of studies, ethnicity, publication year, or definition of MetS. As for CRC mortality, further stratified analyses indicated statistical significance in studies with assessing cancer-specific survival outcome, in male, a cohort design, ethnicity of non-Chinese or with definition of MetS as ≥ 3 metabolic abnormalities. Obesity and hyperglycemia are risk factors of CRC incidence in both male and female. Only dysglycemia is the risk factor for CRC mortality. Conclusions: MetS is associated with an increased risk of CRC incidence and cancer-specific mortality, but not overall mortality. In addition, MetS may increase the CRC mortality in male rather than in female. However, since most of the studies on CRC mortality were conducted in Chinese, further studies are needed to clarify this connection.

show abstract

“…Univariate logistic regression analysis indicated that WHR, LDL-C, FABP4, FABP6, CEA, and family history of CRC were risk factors for CRC, and HDL-C was a protective factor. According to the results of univariate logistic regression and the previous studies about the impact of metabolic syndrome on CRC [23], we adjusted for WHR, SBP, DBP, LDL-C, HDL-C, CEA, and family history of CRC in multivariate logistic regression analysis (sample size 200), the results still showed that FABP4 and FABP6 are independent risk factors for CRC development (adjusted odds ratio 1.916; 95%CI 1.340–2.492; P < 0.001; adjusted odds ratio 2.162; 95%CI 1.046, 1.078); P < 0.001, respectively) (Table 4).…”

Section: Resultsmentioning

confidence: 99%

High expression of FABP4 and FABP6 in patients with colorectal cancer

et al. 2019

View full text Add to dashboard Cite

ObjectiveTo explore the relationship between FABP4 and FABP6 expression and the pathogenesis of colorectal cancer (CRC) and their potential as biomarkers in the diagnosis of CRC.MethodsIn total, 100 CRC patients and 100 controls were enrolled. The serum levels of FABP4 and FABP6 were detected by enzyme-linked immunosorbent assay (ELISA) before and 2 weeks after radical resection of CRC. The protein expressions of FABP4 and FABP6 were observed in colorectal tumor tissues and adjacent tissues by immunohistochemistry and western blot, respectively. The diagnostic performance of FABP4 and FABP6 in patients with CRC was evaluated by receiver operating characteristic (ROC) curve analysis.ResultsThe serum levels of FABP4 and FABP6 in patients with CRC were higher than the levels in the controls before surgery (P < 0.001), and significantly decreased at 2 weeks after operation (P < 0.001). Immunohistochemistry showed that FABP4 and FABP6 were mainly distributed in the cytoplasm of human colorectal tumor tissues, and only a small amount distributed in adjacent tissues. Western blot revealed that the protein expressions of FABP4 and FABP6 were significantly higher in tumor tissues than in adjacent tissues (P < 0.001, P = 0.002, respectively). Tumors with high and low FABP4 and FABP6 expression have no significant correlation in tumor size, tumor site, distant organ and lymph node metastasis, histologic grade, lymphatic permeation, neurological invasion, vascular invasion, and Duke’s and TNM classification. Multivariate logistic regression analysis showed that FABP4 and FABP6 were independent risk factors for CRC (adjusted odds ratio 1.916; 95%CI 1.340–2.492; P < 0.001; adjusted odds ratio 2.162; 95%CI 1.046, 1.078); P < 0.001, respectively). In discriminating CRC from the normal control, the optimal sensitivity of FABP4 and FABP6 were 93.20% (95%CI 87.8–96.7) and 83.70% (95%CI 76.7–89.3), respectively, while the optimal specificity of FABP4 and FABP6 were 48.8% (95%CI 39.8–57.9) and 58.4% (95%CI 49.2–67.1), respectively. When combined detection of serum carcinoembryonic (CEA) and FABP4 and FABP6, the optimal sensitivity and specificity were 61.33% (95%CI 53.0–69.2) and 79.82% (95%CI 71.3–86.8), respectively.ConclusionIncreased expression of FABP4 and FABP6 not only were strong risk factors for the development of CRC but could also represent a potential biomarker for CRC diagnosis in Chinese patients. Combined detection of CEA with FABP4 and FABP6 could improve the diagnostic efficacy of CRC.

show abstract

A case-control study of the association between metabolic syndrome and colorectal cancer: a comparison of International Diabetes Federation, National Cholesterol Education Program Adults Treatment Panel III, and World Health Organization definitions

Cited by 15 publications

References 46 publications

Metabolic Syndrome and Risk of Colorectal Cancer: A Case-Control Study

Metabolic Syndrome and Risk of Colorectal Cancer: A Case-Control Study

The association of Metabolic Syndrome and its Components with the Incidence and Survival of Colorectal Cancer: A Systematic Review and Meta-analysis

High expression of FABP4 and FABP6 in patients with colorectal cancer

Contact Info

Product

Resources

About